Insider · CIK 0001231615
Roger Jeffs
Files at AXSM (Axsome Therapeutics, Inc.), LQDA (Liquidia Corp). First filing Oct 15, 2024, latest Sep 2, 2025.
Where the trades landed
Last year at the 2 companies this insider has traded most, with each buy and sell on the bar it happened.
LQDA: Liquidia Corp
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
AXSM: Axsome Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 40Moderate | Axsome Therapeutics, Inc. | $1.7M 13,464 shares | -19% | +54% from low-10% from high | |
| 38Weak | Axsome Therapeutics, Inc. | $7.3M 60,000 shares | -46% | +52% from low-12% from high | |
| 33Weak | Axsome Therapeutics, Inc. | $4.4M 36,694 shares | -22% | +48% from low-14% from high | |
| 23Weak | Liquidia Corp | $519k 30,610 shares | -3% | +81% from low-9% from high | |
| 32Weak | Liquidia Corp | $192k 14,130 shares | -1% | +42% from low-16% from high | |
| 33Weak | Liquidia Corp | $263k 22,343 shares | -2% | +17% from low-9% from high | |
| 29Weak | Liquidia Corp | $89k 8,053 shares | -1% | +15% from low-0% from high |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 2, 2025 | AXSM Axsome Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -13,464 | $123.68 | $1.7M | 57,510 | Sep 2, 2025 |
| Aug 27, 2025 | AXSM Axsome Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -20,000 | $122.30 | $2.4M | 110,974 | Aug 29, 2025 |
| Aug 28, 2025 | AXSM Axsome Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -20,000 | $121.60 | $2.4M | 90,974 | Aug 29, 2025 |
| Aug 29, 2025 | AXSM Axsome Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -20,000 | $121.27 | $2.4M | 70,974 | Aug 29, 2025 |
| Aug 22, 2025 | AXSM Axsome Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -16,694 | $120.08 | $2.0M | 150,974 | Aug 26, 2025 |
| Aug 26, 2025 | AXSM Axsome Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -20,000 | $120.03 | $2.4M | 130,974 | Aug 26, 2025 |
| Jun 6, 2025 | AXSM Axsome Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +3,166 | $0.00 | $0 | 3,166 | Jun 10, 2025 |
| Jun 6, 2025 | AXSM Axsome Therapeutics, Inc. | AGrant or award Restricted Stock Unitsderivative | +1,429 | $0.00 | $0 | 1,429 | Jun 10, 2025 |
| Jun 3, 2025 | LQDA Liquidia Corp | MOption exercise Common Stock10b5-1 | +69,169 | - | - | 1,075,589 | Jun 5, 2025 |
| Jun 4, 2025 | LQDA Liquidia Corp | SOpen-market sale Common Stock10b5-1 | -30,610 | $16.97 | $519k | 1,044,979 | Jun 5, 2025 |
| Jun 3, 2025 | LQDA Liquidia Corp | MOption exercise Performance Stock Unitsderivative10b5-1 | -69,169 | $0.00 | $0 | 152,169 | Jun 5, 2025 |
| Apr 14, 2025 | LQDA Liquidia Corp | SOpen-market sale Common Stock10b5-1 | -14,130 | $13.57 | $192k | 1,006,420 | Apr 16, 2025 |
| Feb 21, 2025 | AXSM Axsome Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +1,408 | $0.00 | $0 | 1,408 | Feb 25, 2025 |
| Jan 11, 2025 | LQDA Liquidia Corp | AGrant or award Common Stock10b5-1 | +229,327 | $0.00 | $0 | 1,041,520 | Jan 14, 2025 |
| Jan 14, 2025 | LQDA Liquidia Corp | SOpen-market sale Common Stock10b5-1 | -22,343 | $11.78 | $263k | 1,019,177 | Jan 14, 2025 |
| Jan 11, 2025 | LQDA Liquidia Corp | AGrant or award Performance Stock Unitsderivative10b5-1 | +229,327 | $0.00 | $0 | 229,327 | Jan 14, 2025 |
| Oct 14, 2024 | LQDA Liquidia Corp | SOpen-market sale Common Stock10b5-1 | -8,053 | $11.11 | $89k | 812,193 | Oct 15, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.